Mitochondria repair in mice may provide answers on Parkinson’s disease
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
List view / Grid view
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
Researchers have added to evidence that farnesol prevents and reverses brain damage linked to Parkinson’s disease in mouse models.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
UK researchers have created a metal-based molecule that inhibits the build-up of Alzheimer’s-associated peptide, amyloid-β, in lab tests.
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
Using deep machine learning, researchers have completed the activity profiles, from chemistry to clinical level, for one million molecules.
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
In cell cultures, a compound named STM2457 was shown to interfere with coronavirus replication, making it a potential treatment for SARS-CoV-2.
A new algorithm called MolDiscovery uses mass spectrometry data from molecules to predict their identity and whether they are unknown substances.
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
A new promising sarcoma target, phosphodiesterase 3A (PDE3A), and drugs targeting it have been identified by researchers at the University of Helsinki. Dr Katja Ivanitskiy, Dr Harri Sihto and Professor Olli Kallioniemi outline emerging evidence that indicates PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular…
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
A major challenge during high-throughput and fragment screening is the potential for identifying ‘frequent hitters’ – compounds that affect unrelated targets. Matthew Lloyd from the University of Bath explains why these hits can arise during drug discovery and how machine learning could be the answer to identifying these compounds.